Depletion of regulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab

Abstract

The CC chemokine receptor 4 (CCR4) is highly expressed on type 2 helper T cells and regulatory T (Treg) cells. Mogamulizumab, an anti-CCR4 antibody, reduces the numbers of CCR4⁺ malignant T cells and CCR4⁺ Treg cells in cutaneous T-cell lymphoma. Depleting Treg cells by targeting CCR4 has great potential in cancer immunotherapies.

Keywords:

• cutaneous T-cell lymphoma
• chemokine receptor
• mogamulizumab
• mycosis fungoides
• monoclonal antibody
• regulatory T cells
• Sézary syndrome
• targeted therapy

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.